• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑脊液和血液生物标志物用于帕金森病的诊断。

CSF and blood biomarkers for Parkinson's disease.

机构信息

Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine, University of Perugia, Perugia, Italy.

Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy.

出版信息

Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10.

DOI:10.1016/S1474-4422(19)30024-9
PMID:30981640
Abstract

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease-the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain. A combination of multiple CSF biomarkers has emerged as an accurate diagnostic and prognostic model. With respect to early diagnosis, the measurement of CSF α-synuclein aggregates is providing encouraging preliminary results. Blood α-synuclein species and neurofilament light chain are also under investigation because they would provide a non-invasive tool, both for early and differential diagnosis of Parkinson's disease versus atypical parkinsonian disorders, and for disease monitoring. In view of adopting CSF and blood biomarkers for improving Parkinson's disease diagnostic and prognostic accuracy, further validation in large independent cohorts is needed.

摘要

在帕金森病的管理中,迫切需要可靠的诊断和预后生物标志物。帕金森病的诊断主要依赖于临床症状,这阻碍了对疾病最早阶段的检测——此时使用即将出现的疾病修饰药物治疗可能具有最大的治疗效果。可靠的预后标志物有助于预测对治疗的反应。有证据表明,与帕金森病病理生理学密切相关的 CSF 和血液生物标志物具有潜在的诊断和预后价值,如α-突触核蛋白物种、溶酶体酶、淀粉样蛋白和 tau 病理标志物以及神经丝轻链。多种 CSF 生物标志物的组合已成为一种准确的诊断和预后模型。就早期诊断而言,CSF α-突触核蛋白聚集体的测量提供了令人鼓舞的初步结果。血液α-突触核蛋白物种和神经丝轻链也在研究中,因为它们将为帕金森病与非典型帕金森病障碍的早期和鉴别诊断以及疾病监测提供一种非侵入性工具。鉴于采用 CSF 和血液生物标志物来提高帕金森病诊断和预后的准确性,需要在大型独立队列中进一步验证。

相似文献

1
CSF and blood biomarkers for Parkinson's disease.脑脊液和血液生物标志物用于帕金森病的诊断。
Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10.
2
Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.帕金森病中的 Tau/α-突触核蛋白比值与炎症蛋白:一项探索性研究。
Mov Disord. 2017 Jul;32(7):1066-1073. doi: 10.1002/mds.27001. Epub 2017 May 26.
3
Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.用于帕金森病的脑脊液生物标志物的发现、验证与优化
Expert Rev Mol Diagn. 2017 Aug;17(8):771-780. doi: 10.1080/14737159.2017.1341312. Epub 2017 Jun 19.
4
Update on CSF Biomarkers in Parkinson's Disease.帕金森病脑脊液生物标志物研究进展。
Biomolecules. 2022 Feb 18;12(2):329. doi: 10.3390/biom12020329.
5
Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers.揭示帕金森病的病理生理机制:脑脊液生物标志物的作用
Biomark Insights. 2020 Oct 12;15:1177271920964077. doi: 10.1177/1177271920964077. eCollection 2020.
6
CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.CSF 或血清神经丝轻链添加到 α-突触核蛋白检测面板可区分帕金森病与对照组。
Mov Disord. 2020 Feb;35(2):288-295. doi: 10.1002/mds.27897. Epub 2019 Nov 18.
7
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.帕金森病患者脑脊液中α-突触核蛋白和tau 浓度:一项队列研究。
Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X.
8
Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.寡聚α-突触核蛋白和β-淀粉样蛋白变体作为帕金森病和阿尔茨海默病的潜在生物标志物。
Eur J Neurosci. 2016 Jan;43(1):3-16. doi: 10.1111/ejn.13056. Epub 2015 Oct 15.
9
Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review.帕金森病的脑脊液生物标志物——一项系统综述
Acta Neurol Scand. 2017 Jan;135(1):34-56. doi: 10.1111/ane.12590. Epub 2016 Mar 18.
10
CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.脑脊液 α-突触核蛋白和 UCH-L1 在帕金森病和非典型帕金森综合征中的水平。
Parkinsonism Relat Disord. 2014 Apr;20(4):382-7. doi: 10.1016/j.parkreldis.2014.01.011. Epub 2014 Jan 22.

引用本文的文献

1
Safety and Feasibility of Serial Lumbar Punctures: Long-term Results from the Parkinson's Progression Markers Initiative.连续腰椎穿刺的安全性与可行性:帕金森病进展标志物计划的长期结果
Clin Park Relat Disord. 2025 Aug 13;13:100385. doi: 10.1016/j.prdoa.2025.100385. eCollection 2025.
2
Impairment of the intracranial lymphatic system in Parkinson's disease: a combined study of the meningeal lymphatics vessels and glymphatic system based on noninvasive neuroimaging.帕金森病中颅内淋巴系统的损伤:基于无创神经影像学对脑膜淋巴管和类淋巴系统的联合研究
Eur J Med Res. 2025 Aug 25;30(1):801. doi: 10.1186/s40001-025-03048-7.
3
Adaptive immunity in the pathogenesis and treatments of Parkinson's disease.
适应性免疫在帕金森病发病机制及治疗中的作用
NeuroImmune Pharm Ther. 2025 Jun 20;4(2):273-284. doi: 10.1515/nipt-2025-0008. eCollection 2025 Jun.
4
PANDA study: subtyping of Parkinson's disease - cohort study protocol.熊猫研究:帕金森病的亚型分类——队列研究方案。
BMJ Open. 2025 Jul 30;15(7):e102417. doi: 10.1136/bmjopen-2025-102417.
5
Unlocking the potential of circulating small extracellular vesicles in neurodegenerative disease through targeted biomarkers and advancements in biosensing.通过靶向生物标志物和生物传感技术的进步,释放循环小细胞外囊泡在神经退行性疾病中的潜力。
Explor Biomat X. 2024;1(2):100-123. doi: 10.37349/ebmx.2024.00008. Epub 2024 Apr 24.
6
The Progression of NUS1-Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR.NUS1相关帕金森病的进展及血浆NgBR的诊断潜力
CNS Neurosci Ther. 2025 Jul;31(7):e70549. doi: 10.1111/cns.70549.
7
Exploring sphingolipid metabolism-related biomarkers for Parkinson's disease: a transcriptomic analysis.探索帕金森病中与鞘脂代谢相关的生物标志物:一项转录组分析。
Front Neurol. 2025 Jun 4;16:1548322. doi: 10.3389/fneur.2025.1548322. eCollection 2025.
8
Advances in Circulating Biomarkers for Neurodegenerative Diseases, Traumatic Brain Injuries, and Central Nervous System Tumors.神经退行性疾病、创伤性脑损伤和中枢神经系统肿瘤循环生物标志物的进展
Ann Lab Med. 2025 Jul 1;45(4):381-390. doi: 10.3343/alm.2024.0611. Epub 2025 Jun 18.
9
KLVFF Functionalized Graphene Oxide for Aβ Peptide Electrical Detection: A Promising Nanomaterial for the Development of Alzheimer's Disease Diagnostic Devices.用于β淀粉样肽电学检测的KLVFF功能化氧化石墨烯:一种用于开发阿尔茨海默病诊断设备的有前景的纳米材料。
Small. 2025 Aug;21(32):e2503488. doi: 10.1002/smll.202503488. Epub 2025 Jun 16.
10
CSF Biomarker-Based Cognitive Trajectories in Parkinson's Disease-Subjective Cognitive Decline.帕金森病-主观认知衰退中基于脑脊液生物标志物的认知轨迹
Ann Clin Transl Neurol. 2025 Aug;12(8):1575-1584. doi: 10.1002/acn3.70075. Epub 2025 Jun 11.